Trial · NCT00787267
Adverse events46
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 46
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | anorexia | General disorders | Evalulable Patients That Received Dasatinib | 6 | 25 | |
| other | bronchospasm (wheezing) | Respiratory, thoracic and mediastinal disorders | Evalulable Patients That Received Dasatinib | 2 | 25 | |
| other | decreased hemoglobin | Blood and lymphatic system disorders | Evalulable Patients That Received Dasatinib | 8 | 25 | |
| other | decreased neutrophils | Blood and lymphatic system disorders | Evalulable Patients That Received Dasatinib | 1 | 25 | |
| other | diarrhea | Gastrointestinal disorders | Evalulable Patients That Received Dasatinib | 3 | 25 | |
| other | dizziness (lightheadedness) | General disorders | Evalulable Patients That Received Dasatinib | 1 | 25 | |
| other | dyspnea | Respiratory, thoracic and mediastinal disorders | Evalulable Patients That Received Dasatinib | 2 | 25 | |
| other | edema (periorbital/face) | General disorders | Evalulable Patients That Received Dasatinib | 1 | 25 | |
| other | elevated AST | Blood and lymphatic system disorders | Evalulable Patients That Received Dasatinib | 2 | 25 | |
| other | elevated creatinine | Renal and urinary disorders | Evalulable Patients That Received Dasatinib | 1 | 25 | |
| other | elevated LDH | General disorders | Evalulable Patients That Received Dasatinib | 1 | 25 | |
| other | fatigue | General disorders | Evalulable Patients That Received Dasatinib | 8 | 25 | |
| other | flatulence | Gastrointestinal disorders | Evalulable Patients That Received Dasatinib | 1 | 25 | |
| other | hair loss (alopecia) | Skin and subcutaneous tissue disorders | Evalulable Patients That Received Dasatinib | 1 | 25 | |
| other | hypoxia | Respiratory, thoracic and mediastinal disorders | Evalulable Patients That Received Dasatinib | 1 | 25 | |
| other | insomnia | General disorders | Evalulable Patients That Received Dasatinib | 1 | 25 | |
| other | leukocytosis | General disorders | Evalulable Patients That Received Dasatinib | 1 | 25 | |
| other | muscle weakness - lower extremity (leg weakness) | General disorders | Evalulable Patients That Received Dasatinib | 1 | 25 | |
| other | muscle weakness (generalized) | General disorders | Evalulable Patients That Received Dasatinib | 1 | 25 | |
| other | myalgias (generalized) | Musculoskeletal and connective tissue disorders | Evalulable Patients That Received Dasatinib | 1 | 25 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00787267/events